Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry

被引:22
作者
Concheiro, Marta [1 ]
Shakleya, Diaa M. [1 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Biomed Res Ctr, Chem & Drug Metab Sect, Intramural Res Program,NIH, Baltimore, MD 21224 USA
关键词
Umbilical cord; Buprenorphine; LCMS; Ion trap; HUMAN PLASMA; METABOLITE NORBUPRENORPHINE; DEALKYLATED METABOLITE; AMNIOTIC-FLUID; FETAL EXPOSURE; ILLICIT DRUGS; HAIR; VALIDATION; URINE; METHADONE;
D O I
10.1016/j.forsciint.2009.04.005
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A LCMS method was developed and validated for the simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-glucuronide (BUP-Gluc) and norbuprenorphine-glucuronide (NBUP-Gluc) in human umbilical cord. Quantification was achieved by selected ion monitoring of precursor ions m/z 468.4 for BUP; 414.3 for NBUP; 644.4 for BUP-Gluc and 590 for NBUP-Gluc. BUP and NBUP were identified by MS', with m/z 396, 414 and 426 for BUP, and m/z 340, 364 and 382 for NBUP. Glucuronide conjugates were identified by MS3 with m/z 396 and 414 for BUP-Gluc and m/z 340 and 382 for NBUP-Gluc. The assay was linear 1-50 ng/g. Intra-day, inter-day and total assay imprecision (%RSD) were <14.5%, and analytical recovery ranged from 94.1% to 112.3% for all analytes. Extraction efficiencies were >66.3%, and process efficiency >73.4%. Matrix effect ranged, in absolute value, from 3.7% to 7.4% (CV < 2 1.8%, n = 8). The method was selective with no endogenous or exogenous interferences from 41 compounds evaluated. Sensitivity was high with limits of detection of 0.8 ng/g. In order to prove method applicability, an authentic umbilical cord obtained from an opioid-dependent pregnant woman receiving BUP pharmacotherapy was analyzed. Interestingly, BUP was not detected but concentrations of the other metabolites were NBUP-Gluc 13.4 ng/g, BUP-Gluc 3.5 ng/g and NBUP 1.2 ng/g. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 49 条
[11]   Bioanalytical procedures for monitoring in utero drug exposure [J].
Gray, Teresa ;
Huestis, Marilyn .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2007, 388 (07) :1455-1465
[12]   Quantification of nicotine, cotinine, trans-3′-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry [J].
Gray, Teresa R. ;
Shakleya, Diaa M. ;
Huestis, Marilyn A. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 863 (01) :107-114
[13]   Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry [J].
Grimm, D ;
Pauly, E ;
Pöschl, J ;
Linderkamp, O ;
Skopp, G .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :526-530
[14]   Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS [J].
Hegstad, S. ;
Khiabani, H. Z. ;
Oiestad, E. L. ;
Berg, T. ;
Christophersen, A. S. .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2007, 31 (04) :214-219
[15]   Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography mass spectrometry [J].
Hoja, H ;
Marquet, P ;
Verneuil, B ;
Lotfi, H ;
Dupuy, JL ;
Lachatre, G .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1997, 21 (02) :160-165
[16]   The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry [J].
Huang, W ;
Moody, DE ;
McCance-Katz, EF .
THERAPEUTIC DRUG MONITORING, 2006, 28 (02) :245-251
[17]   Urinary buprenorphine concentrations in patients treated with Suboxone® as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay [J].
Hull, Mindy J. ;
Bierer, Michael F. ;
Griggs, David A. ;
Long, William H. ;
Nixon, Andrea L. ;
Flood, James G. .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2008, 32 (07) :516-521
[18]   Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome [J].
Jones, HE ;
Johnson, RE ;
Jasinski, DR ;
O'Grady, KE ;
Chisholm, CA ;
Choo, RE ;
Crocetti, M ;
Dudas, R ;
Harrow, C ;
Huestis, MA ;
Jansson, LM ;
Lantz, M ;
Lester, BM ;
Milio, L .
DRUG AND ALCOHOL DEPENDENCE, 2005, 79 (01) :1-10
[19]   Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes [J].
Kacinko, S. L. ;
Jones, H. E. ;
Johnson, R. E. ;
Choo, R. E. ;
Huestis, M. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) :604-612
[20]   Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine [J].
Kacinko, Sherri L. ;
Concheiro-Guisan, Marta ;
Shakleya, Diaa M. ;
Huestis, Marilyn A. .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 392 (05) :903-911